Theravance Biopharma (NASDAQ: TBPH) reported Q2 EPS of ($0.11), $0.10 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $11.1 million versus the consensus estimate of $12.5 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.